Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) (ADVANCE2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04274452
Recruitment Status : Withdrawn (The ARGX-113-1908 study will be replaced by a similar design with a subcutaneous formulation (ARGX-113-2004))
First Posted : February 18, 2020
Last Update Posted : September 14, 2020
Sponsor:
Information provided by (Responsible Party):
argenx

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : September 1, 2021
Estimated Study Completion Date : September 1, 2021